ArticleF1000Research2026
Web-based Machine Learning Model for Predicting Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Multicenter Study.
Article in F1000Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a serious complication of type 2 diabetes (T2DM), particularly in low- and middle-income countries with limited access to early diagnosis. Predicting CKD risk using routine clinical data could enable earlier nephroprotective care. This study developed and internally validated a machine learning-based web application to predict incident CKD among T2DM patients in Indonesia's national health insurance program (Prolanis). Methods: A machine learning prediction model was conducted using BPJS Prolanis data (2017-2023). Adults (≥18 years) with T2DM and no prior CKD were included. Six algorithms (Logistic Regression, Random Forest, Decision Tree, XGBoost, LightGBM, CatBoost) were trained on 80% of the data and internally validated on the remaining 20% to predict CKD. Performance was assessed via accuracy, precision, recall, F1 score, and AUC. SHAP was used for interpretability. Results: Among 7,581 individuals, 864 (11.4%) developed CKD. CatBoost achieved the best performance (AUC = 0.847, accuracy = 0.797, precision = 0.643, recall = 0.525, F1 = 0.578). SHAP identified rapid-acting insulin analogues, amlodipine, furosemide, high blood urea nitrogen, and folic acid as key positive predictors. Advanced age and higher comorbidity burden increased risk, while chronic ischaemic heart disease and dental pulp diseases appeared protective-likely due to healthcare utilization bias. A web-based risk calculator was developed. Conclusions: The CatBoost-based web app demonstrated strong discriminative ability for predicting incident CKD in T2DM patients using routine claims data. This tool may support risk stratification in primary care settings across Indonesia and similar low-resource environments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.